MULTI-COMPONENT PHARMACEUTICALS FOR TREATING DIABETES

• US 20110319325A1
• Filed: 06/27/2011
• Published: 12/29/2011
• Est. Priority Date: 06/28/2010
• Status: Abandoned Application

• Current Assignee: Complexa, Inc.
• Original Assignee: Complexa, Inc.
• Inventors: Miller, Raymond A.
• Application Number:
  US13/169,740
• Publication Number:
  US 20110319325A1
• Time in Patent Office: Days
• US Class Current: 514/6.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/201 having one or two double bonds, e.g. oleic, linoleic acids
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat diabetes, and methods for preparing activated fatty acids are provided herein.

Claims

1. A method for treating diabetes comprising administering to an individual in need of treatment a fatty acid component enriched for one or more activated fatty acids.

2. The method of claim 1, wherein the one or more activated fatty acids selected from the group consisting of nitro-linoleic acid, keto-linoleic acid, nitro-oleic acid, and keto-oleic acid.

3. The method of claim 1, wherein the fatty acid component is nitro-oleic acid.

4. The method of claim 1, wherein the fatty acid component comprises about 1 mg to about 3000 of the one or more activated fatty acids.

5. The method of claim 1, wherein the fatty acid component further comprises one or more non-activated fatty acid selected from the group consisting of linoleic acid, α

-linoleic acid, γ

-linoleic acid, oleic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and derivatives and combinations thereof.

6. The method of claim 5, wherein the ratio of activated fatty acid to non-activated acid is from about 99:

1 to about 1;

99.

7. The method of claim 1, further comprising administering one or more secondary agents concurrently with or within the same course of treatment with the fatty acid component enriched for one or more activated fatty acids, wherein the one or more secondary agents are selected from the group consisting of insulin sensitizers, DPP IV inhibitors, GLP1 analogs, and insulin secretagogues.

8. The method of claim 7, wherein the one or more secondary agents are covalently linked to at least a portion of the fatty acid component.

9. The method of claim 1, further comprising administering one or more secondary agents concurrently with or within the same course of treatment with the fatty acid component enriched for one or more activated fatty acids, wherein the one or more secondary agents are selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, MCC-555, rivoglitazone, and ciglitazone.

10. The method of claim 9, wherein the one or more secondary agents are covalently linked to at least a portion of the fatty acid component.

11. The method of claim 1, further comprising administering concurrently or within the same course of treatment with the activated fatty acid vitamin E or a derivative thereof.

12. The method of claim 1, further comprising administering concurrently or within the same course of treatment with the activated fatty acid one or more additional agents selected from vitamin A, vitamin B, vitamin B-1, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin D3, vitamin E, selenium, β

-carotene, ginko biloba, goldenseal, valerian, ginseng, echinacea, grape seed extracts, ephedra, yucca concentrates, green tea extract, rice bran extract, wheat germ, wheat germ extract, beeswax, red yeast rice extract, stevia leaf extract, flaxseed oil, borage seed oil, coenzyme Q10, glucosamine derivatives, methylsulfonylmethane, pantothenic acid, biotin, thiamin, riboflavin, niacin, folic acid, palmitic acid, and derivatives thereof.

13. The method of claim 1, further comprising administering insulin concurrently or within the same course of treatment with the activated fatty acid.

14. The method of claim 1, further comprising administering insulin after administering the fatty acid component.

15. The method of claim 1, wherein the fatty acid component is contained in a pharmaceutical composition, said pharmaceutical composition comprising:

the one or more activated fatty acids; and

a pharmaceutically acceptable carrier or excipient.

16. The method of claim 1, wherein the fatty acid component is contained in a dietary supplement, said dietary supplement comprising:

the one or more activated fatty acids; and

a neutraceutically acceptable carrier.

17. A pharmaceutical composition comprising:

an effective amount of one or more activated fatty acids;

an effective amount of one or more secondary agents selected from the group consisting of insulin sensitizers, DPP IV inhibitors, GLP1 analogs, and insulin secretagogues; and

a pharmaceutically acceptable excipient or carrier.

18. The pharmaceutical composition of claim 17, wherein the one or more secondary agents are selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, MCC-555, rivoglitazone, and ciglitazone.

19. The pharmaceutical composition of claim 17, wherein the one or more secondary agents are rosiglitazone.

20. The pharmaceutical composition of claim 17, further comprising insulin or a pharmacologically active derivative thereof.